Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $20.00 to $18.00. They now have a "buy" rating on the stock.
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target lowered by analysts at Stifel Nicolaus from $27.00 to $23.00. They now have a "buy" rating on the stock.
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates [Yahoo! Finance]
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates